Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

System for time-discretized vacuum ultraviolet spectroscopy of spark breakdown in air.

Ryberg D, Fierro A, Dickens J, Neuber A.

Rev Sci Instrum. 2014 Oct;85(10):103109. doi: 10.1063/1.4897295.

PMID:
25362373
2.

The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung.

Zienolddiny S, Skaug V, Landvik NE, Ryberg D, Phillips DH, Houlston R, Haugen A.

Carcinogenesis. 2009 Aug;30(8):1368-71. doi: 10.1093/carcin/bgp131. Epub 2009 May 22.

PMID:
19465454
3.

A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, Canzian F, Haugen A.

Carcinogenesis. 2008 Jun;29(6):1164-9. doi: 10.1093/carcin/bgn020. Epub 2008 Feb 6.

PMID:
18258609
4.

Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.

Lind H, Ekstrøm PO, Ryberg D, Skaug V, Andreassen T, Stangeland L, Haugen A, Zienolddiny S.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2077-81.

5.

Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer.

Campa D, Zienolddiny S, Lind H, Ryberg D, Skaug V, Canzian F, Haugen A.

Lung Cancer. 2007 Apr;56(1):17-23. Epub 2006 Dec 18.

PMID:
17175058
6.

Msh2 deficiency increases susceptibility to benzo[a]pyrene-induced lymphomagenesis.

Zienolddiny S, Ryberg D, Svendsrud DH, Eilertsen E, Skaug V, Hewer A, Phillips DH, te Riele H, Haugen A.

Int J Cancer. 2006 Jun 1;118(11):2899-902.

7.

Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, Phillips DH, Canzian F, Haugen A.

Carcinogenesis. 2006 Mar;27(3):560-7. Epub 2005 Sep 29.

PMID:
16195237
8.

Chromosome aberrations in tunnel workers exposed to acrylamide and N-methylolacrylamide.

Kjuus H, Hansteen IL, Ryberg D, Goffeng LO, Ovrebø S, Skaug V.

Scand J Work Environ Health. 2005 Aug;31(4):300-6.

9.

Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene.

Lind H, Zienolddiny S, Ryberg D, Skaug V, Phillips DH, Haugen A.

Lung Cancer. 2005 Dec;50(3):285-90. Epub 2005 Aug 26.

PMID:
16126303
10.

Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study.

Raimondi S, Boffetta P, Anttila S, Bröckmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Dragani TA, Garte S, Gsur A, Haidinger G, Hirvonen A, Ingelman-Sundberg M, Kalina I, Lan Q, Leoni VP, Le Marchand L, London SJ, Neri M, Povey AC, Rannug A, Reszka E, Ryberg D, Risch A, Romkes M, Ruano-Ravina A, Schoket B, Spinola M, Sugimura H, Wu X, Taioli E.

Mutat Res. 2005 Dec 30;592(1-2):45-57. Epub 2005 Jul 11.

PMID:
16009381
11.

Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway.

Skuladottir H, Autrup H, Autrup J, Tjoenneland A, Overvad K, Ryberg D, Haugen A, Olsen JH.

Lung Cancer. 2005 May;48(2):187-99. Epub 2004 Dec 15.

PMID:
15829318
12.

CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions.

Vineis P, Veglia F, Anttila S, Benhamou S, Clapper ML, Dolzan V, Ryberg D, Hirvonen A, Kremers P, Le Marchand L, Pastorelli R, Rannug A, Romkes M, Schoket B, Strange RC, Garte S, Taioli E.

Biomarkers. 2004 May-Jun;9(3):298-305.

PMID:
15764294
13.

Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer.

Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A.

Int J Cancer. 2004 Apr 10;109(3):353-6.

14.

Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States).

Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S, Haugen A, Ingelman-Sundberg M, Kihara M, Rannug A, Ryberg D, Stücker I, Sugimura H, Taioli E.

Cancer Causes Control. 2003 May;14(4):339-46.

PMID:
12846365
15.

Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk.

Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D, Brockmöller J, Clapper ML, Daly A, Dolzan V, Ford J, Gaspari L, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Ingelman-Sundberg M, Kalina I, Kihara M, Kremers P, Le Marchand L, London SJ, Nazar-Stewart V, Onon-Kihara M, Rannug A, Romkes M, Ryberg D, Seidegard J, Shields P, Strange RC, Stücker I, To-Figueras J, Brennan P, Taioli E.

Carcinogenesis. 2002 Aug;23(8):1343-50. Erratum in: Carcinogenesis 2002 Oct;23(10):1771.

PMID:
12151353
16.

Metabolic gene polymorphism frequencies in control populations.

Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell'Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Stücker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E.

Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48.

17.

Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung.

Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, Harris CC.

Cancer Res. 2001 Sep 1;61(17):6350-5.

18.

Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.

Zienolddiny S, Ryberg D, Arab MO, Skaug V, Haugen A.

Br J Cancer. 2001 Jan;84(2):226-31.

19.

Induction of microsatellite mutations by oxidative agents in human lung cancer cell lines.

Zienolddiny S, Ryberg D, Haugen A.

Carcinogenesis. 2000 Aug;21(8):1521-6.

PMID:
10910953
20.

Nickel(II) induces microsatellite mutations in human lung cancer cell lines.

Zienolddiny S, Svendsrud DH, Ryberg D, Mikalsen AB, Haugen A.

Mutat Res. 2000 Jul 20;452(1):91-100.

PMID:
10894895
21.

p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.

Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, Haugen A.

Clin Cancer Res. 2000 Mar;6(3):1031-7.

22.

Gene-environment interactions in human lung cancer.

Haugen A, Ryberg D, Mollerup S, Zienolddiny S, Skaug V, Svendsrud DH.

Toxicol Lett. 2000 Mar 15;112-113:233-7. Review.

PMID:
10720736
23.

Hras1 VNTR alleles as susceptibility markers for lung cancer: relationship to microsatellite instability in tumors.

Lindstedt BA, Ryberg D, Zienolddiny S, Khan H, Haugen A.

Anticancer Res. 1999 Nov-Dec;19(6C):5523-7.

PMID:
10697610
24.

GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients.

Hou SM, Ryberg D, Fält S, Deverill A, Tefre T, Børresen AL, Haugen A, Lambert B.

Carcinogenesis. 2000 Jan;21(1):49-54.

PMID:
10607733
25.

DNA mismatch binding in human lung tumor cell lines.

Zienolddiny S, Ryberg D, Gazdar AF, Haugen A.

Lung Cancer. 1999 Oct;26(1):15-25.

PMID:
10574677
26.

Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients.

Mollerup S, Ryberg D, Hewer A, Phillips DH, Haugen A.

Cancer Res. 1999 Jul 15;59(14):3317-20.

27.
28.

Glutathione S-transferase M1 and P1 genotypes and urinary excretion of 1-hydroxypyrene in coke oven workers.

Ovrebø S, Ryberg D, Haugen A, Leira HL.

Sci Total Environ. 1998 Sep 4;220(1):25-31.

PMID:
9800384
29.

Absence of mutations in the transforming growth factor-beta type II receptor in sporadic lung cancers with microsatellite instability and rare H-ras1 alleles.

Takenoshita S, Hagiwara K, Gemma A, Nagashima M, Ryberg D, Lindstedt BA, Bennett WP, Haugen A, Harris CC.

Carcinogenesis. 1997 Jul;18(7):1427-9.

PMID:
9230292
30.

Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk.

Ryberg D, Skaug V, Hewer A, Phillips DH, Harries LW, Wolf CR, Ogreid D, Ulvik A, Vu P, Haugen A.

Carcinogenesis. 1997 Jul;18(7):1285-9.

PMID:
9230269
31.
32.

p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels.

Kure EH, Ryberg D, Hewer A, Phillips DH, Skaug V, Baera R, Haugen A.

Carcinogenesis. 1996 Oct;17(10):2201-5.

PMID:
8895489
33.

A hereditary genetic marker closely associated with microsatellite instability in lung cancer.

Ryberg D, Lindstedt BA, Zienolddiny S, Haugen A.

Cancer Res. 1995 Sep 15;55(18):3996-9.

34.

Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients.

Ryberg D, Hewer A, Phillips DH, Haugen A.

Cancer Res. 1994 Nov 15;54(22):5801-3.

35.

Nickel-induced alterations in human renal epithelial cells.

Haugen A, Maehle L, Mollerup S, Rivedal E, Ryberg D.

Environ Health Perspect. 1994 Sep;102 Suppl 3:117-8.

36.

p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer.

Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Børresen AL, Haugen A.

Cancer Res. 1994 Mar 15;54(6):1551-5.

37.

Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome.

Peltomäki P, Lothe RA, Aaltonen LA, Pylkkänen L, Nyström-Lahti M, Seruca R, David L, Holm R, Ryberg D, Haugen A, et al.

Cancer Res. 1993 Dec 15;53(24):5853-5.

PMID:
8261393
38.

Rare Ha-ras1 alleles and predisposition to testicular cancer.

Ryberg D, Heimdal K, Fosså SD, Børresen AL, Haugen A.

Int J Cancer. 1993 Apr 1;53(6):938-40.

PMID:
8097187
39.

Allele diversity of the H-ras-1 variable number of tandem repeats in Norwegian lung cancer patients.

Ryberg D, Tefre T, Skaug V, Stangeland L, Ovrebø S, Naalsund A, Børresen AL, Haugen A.

Environ Health Perspect. 1992 Nov;98:187-9.

40.

No alterations in exon 21 of the RB1 gene in sarcomas and carcinomas of the breast, colon, and lung.

Hovig E, Smith-Sørensen B, Gebhardt MC, Ryberg D, Lothe R, Børresen AL.

Genes Chromosomes Cancer. 1992 Sep;5(2):97-103.

PMID:
1381957
41.

Altered p53 gene structure and expression in human epithelial cells after exposure to nickel.

Maehle L, Metcalf RA, Ryberg D, Bennett WP, Harris CC, Haugen A.

Cancer Res. 1992 Jan 1;52(1):218-21.

42.
43.

Ha-ras-1 alleles in Norwegian lung cancer patients.

Ryberg D, Tefre T, Ovrebø S, Skaug V, Stangeland L, Naalsund A, Baera R, Børresen AL, Haugen A.

Hum Genet. 1990 Nov;86(1):40-4.

PMID:
1979305
44.

Neoplastic transformation of a human kidney epithelial cell line transfected with v-Ha-ras oncogene.

Haugen A, Ryberg D, Hansteen IL, Amstad P.

Int J Cancer. 1990 Mar 15;45(3):572-7.

PMID:
2407668
45.

Mechanisms of chromium toxicity in mitochondria.

Ryberg D, Alexander J.

Chem Biol Interact. 1990;75(2):141-51.

PMID:
2369782
46.

Transformation of human kidney epithelial cells to tumorigenicity by nickel(II) and V-HA-RAS oncogene.

Haugen A, Ryberg D, Hansteen IL, Dalen H.

Biol Trace Elem Res. 1989 Jul-Sep;21:451-8.

PMID:
2484627
47.

[Cancer--occupational exposure and genetics].

Haugen A, Ryberg D, Skaug V, Ovrebø S.

Tidsskr Nor Laegeforen. 1989 May 20;109(14):1529-34. Norwegian.

PMID:
2749642
48.

Microsomal metabolism of hexavalent chromium. Inhibitory effect of oxygen and involvement of cytochrome P-450.

Mikalsen A, Alexander J, Ryberg D.

Chem Biol Interact. 1989;69(2-3):175-92.

PMID:
2495190
49.

Problems with methods for measurement of hexavalent chromium applied to biological samples.

Ryberg D.

Acta Pharmacol Toxicol (Copenh). 1986;59 Suppl 7:624-6. No abstract available.

PMID:
3776640
50.

Supplemental Content

Loading ...
Support Center